Brief: Candel Therapeutics Announces Proposed $100 Million Public Offering
19/02/2026 21:42
Candel Therapeutics Inc CADL.O: CANDEL THERAPEUTICS ANNOUNCES PROPOSED $100 MILLION PUBLIC OFFERING CANDEL THERAPEUTICS INC - PROCEEDS TO FUND AGLATIMAGENE LAUNCH AND PHASE 3 TRIAL COSTS Source text: ID:nGNX4gzjcG Further company coverage: CADL.O
Recent news on Candel Therapeutics
See all newsBrief: Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints In Patients From Phase 3 Trial Of Aglatimagene Besadenovec (Can-2409)
Candel Therapeutics reports Q1 loss
Brief: Candel Therapeutics Q1 Net Income USD -8.861 Million
Brief: Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Candel Therapeutics Inc Extended Survival Tail Observed In Trial Of Aglatimagene Besadenovec